Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X:
“The KRAS era has finally arrived in oncology.
Key insights from the evolving landscape of KRAS inhibitors:
- KRAS mutations drive ~20% of cancers
- KRASG12C inhibitors show strongest activity in NSCLC
- Combination strategies critical in CRC
- Resistance remains the major challenge
- Next-gen pan-KRAS and pan-RAS inhibitors in development.”
Title: Emerging landscape of KRAS inhibitors in cancer treatment
Authors: Jakob M. Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi S. Patel, Ferran Fece de la Cruz, Doga C. Gulhan, Ryan B. Corcoran
Read the Full Article.
“How often is chemotherapy modified in real-world breast cancer care?
Real-world cohort (n=12,558): 36% received modified chemotherapy
Most common:
- Decreased Dose intensity (ARDI <90%)
- Early discontinuation
- Treatment delays
Higher risk with:
- ≥4 drugs
- ≥17 cycles
- Neoadjuvant therapy
- HER2-targeted regimens
Important reminder: trial efficacy ≠ real-world delivery.”
Title: The landscape of chemotherapy modifications among women treated for stage I–IIIA breast cancer
Authors: Jenna Bhimani, Kelli O’Connell, Victoria S. Blinder, Rachael Burganowski, Isaac J. Ergas, Grace B. Gallagher, Jennifer J. Griggs, Narre Heon, Sankeerth Jinna, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke, Cecile A. Laurent, Raymond Liu, Kanichi G. Nakata, Sonia Persaud, Janise M. Roh, Emily Valice, Elisa V. Bandera, Erin J. Aiello Bowles, Lawrence H. Kushi, Elizabeth D. Kantor
Read the Full Article.
“Must read article from JAMA Network
Physician training saves lives-but trainees need protection too.
Key findings from JAMA Netw Open 2025:
- Suicide = leading cause of death in US residents
- Risk peaks during early residency transitions
- Specialty-specific risks also observed
With intense workloads in Indian residency, prioritizing doctor well-being is critical.”
Title: Causes of Death Among US Medical Residents
Authors: Nicholas A. Yaghmour, William E. Bynum IV, Frederic W. Hafferty, Karen D. Könings, Thomas Richter, Timothy P. Brigham, Thomas J. Nasca
Read the Full Article.
Other articles featuring Karamvir Yadav on OncoDaily.